BCHT HSV-2 mRNA vaccine
phase 1 Changchun BCHT Biotechnology Co.
Last updated:
| Developer | Changchun BCHT Biotechnology Co. |
|---|---|
| Platform | mRNA |
| HSV target | HSV-2 |
| Approach | unclear |
| Phase | phase 1 |
| Status | A Phase 1 dose-escalation trial started in 2025 and is enrolling by invitation, with primary completion listed for 2027; no results are posted. |
| Trials | NCT07330440 |
This is an mRNA vaccine against HSV-2 whose registered trial is sponsored by Changchun BCHT Biotechnology Co. Its phase 1 dose-escalation trial, NCT07330440, is evaluating safety, tolerability and immunogenicity in healthy participants aged 18-55, stratified by serostatus. As of the 2026-09-27 registry search, that trial was the one record found and was enrolling by invitation, with no results posted.
What it is
The registry describes it as an mRNA vaccine against herpes simplex virus type 2 (HSV-2), with Changchun BCHT Biotechnology Co. as lead sponsor. The sources do not name the HSV-2 proteins the mRNA encodes.
Where it stands
NCT07330440 is a phase 1 dose-escalation study of safety, tolerability and immunogenicity. It is in healthy participants aged 18-55, stratified by serostatus, and lists genital herpes as the condition. The record lists low-, mid- and high-dose cohorts and a placebo group. Its status is enrolling by invitation, with an estimated enrollment of 144 and a start in 2025. The registry lists primary completion for 2027; this is a planned date, not a result. A ClinicalTrials.gov search on 2026-09-27 for records naming the vaccine returned 1 record, this trial, which had an ongoing status.
What this does and doesn’t mean
A phase 1 trial being under way shows the vaccine is being tested in people, not that it works; its stated aims are safety, tolerability and immunogenicity. No results are posted on the registry.
Registry snapshot
- Registry status
- Enrolling by invitation
- Phase
- phase 1
- Enrollment
- 144 (estimated)
- Lead sponsor
- Changchun BCHT Biotechnology Co.
- Started
- Oct 13, 2025
- Primary completion
- Mar 4, 2027
Registry record last updated Jan 9, 2026.
Sources
- ClinicalTrials.gov registry search for BCHT HSV mRNA vaccine (searched 2026-09-27)
- A Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) in Healthy Participants Aged 18-55 Years, Stratified by Serostatus (NCT07330440)